Status:
TERMINATED
A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Conditions:
Advanced or Metastatic Solid Tumors
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of Surufatinib plus Sintilimab in Patients with Advanced Solid Tumor
Eligibility Criteria
Inclusion
- Advanced or metastatic and recurrent cancer where an appropriate treatment option is not available
- Have measurable disease based on RECIST 1.1
- Life expectancy \> 12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1
Exclusion
- Any therapy with anti-PD-1, or anti-PD-L1/l2 antibodies or anti-cytotoxic T lymphocyte associated antigen-4 (CTLA-4) antibody (or any other antibody acting on T cell costimulatory or checkpoint pathway) or fruquintinib treatment in previous;
- Prior receipt of Surufatinib
- History of any active autoimmune disease or autoimmune disease, including but not limited to interstitial pneumonia, uveitis, inflammatory bowel disease, hepatitis, pituitary inflammation, vasculitis, systemic lupus erythematosus, etc. (except patients with hypothyroidism that can be controlled only by hormone replacement therapy and patients with type I diabetes who only need insulin replacement therapy)
- History of gastrointestinal perforation and/or fistula, ileus, inflammatory bowel disease, or extensive enterotomy (partial colectomy or extensive enterotomy with chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic diarrhea within 6 months prior to first dosing
- Any life-threatening bleeding event or grade 3 or 4 bleeding requiring blood transfusion, endoscopy, or surgery with 3 months prior to dosing.
Key Trial Info
Start Date :
June 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 27 2021
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04427774
Start Date
June 29 2020
End Date
April 27 2021
Last Update
July 20 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jiangsu Province
Nanjing, China